A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study)
Pautier, Penel, Ray-Coquard, Italiano, Bompas, Delcambre, Bay, Bertucci, Delaye, Chevreau, Cupissol, Bozec, Eymard, Saada, Isambert, Guillemet, Rios, Piperno-Neumann, Chenuc, Duffaud (2020) A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study) Eur J Cancer (IF: 8.4) 125 31-37Links
http://www.ncbi.nlm.nih.gov/pubmed/31835236http://dx.doi.org/10.1016/j.ejca.2019.10.028
